Heberprot-P arrives in the first world: Cuban drug registered in South Korea

Print
Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 
Rating:
( 0 Rating )

Llega Heberprot-P al primer mundo: Registran fármaco cubano en Corea del Sur

A few hours ago, the Center for Genetic Engineering and Biotechnology (CIGB) reported on its Twitter account that the Cuban drug Heberprot-P was registered in South Korea.

This medicine demonstrates the possibility of cure for the healing of complex wounds, ischemic ulcers and those resulting from diabetic foot, which reduces the risks of amputation. It is unique and the first of its kind, it is administered directly to the diabetic's ulcerated tissues, generating an accelerated granulation of the lesions.

The application of the drug Heberprot-P to nearly 290,000 patients in dozens of countries demonstrates the possibility of a cure for the healing of complex wounds, ischemic ulcers and those resulting from diabetic foot, which increases the frequency of granulation formation effective in the lesions treated and therefore reduces the risk of amputation.